Croivalve

Croivalve is a pioneering medical technology startup focused on addressing severe Tricuspid Regurgitation (TR), a condition affecting the heart's tricuspid valve. This condition predominantly impacts elderly patients, leading to symptoms like fatigue, limited exercise tolerance, peripheral edema (swelling), and abdominal swelling. These symptoms often result in frequent hospitalizations and a significantly increased risk of mortality.

The company operates in the healthcare and medical devices market, specifically targeting cardiovascular diseases. Croivalve's primary product is the DUO Tricuspid Coaptation Valve system, a minimally invasive solution designed to treat severe TR. This innovative system combines repair and replacement techniques to provide a comprehensive treatment option. The DUO System consists of two main components: an Anchor System and a Coaptation Valve. The Anchor System connects to the Coaptation Valve and includes a support catheter that can be adjusted and locked into position. This system is anchored within the Superior Vena Cava (SVC) using a stent, allowing for respiratory and cardiac motion. The support catheter has a distal implanted section and a proximal delivery section, which is removed at the end of the procedure. Croivalve's business model revolves around developing and commercializing this advanced medical device. The company generates revenue by selling the DUO Tricuspid Coaptation Valve system to hospitals and healthcare providers. Given the significant unmet clinical need and the lack of effective surgical treatments for TR, Croivalve's solution offers a promising alternative to traditional medical therapy, which only provides temporary relief.

In summary, Croivalve is addressing a critical gap in cardiovascular healthcare with its innovative, minimally invasive treatment for severe Tricuspid Regurgitation. The company's focus on improving patient outcomes and quality of life positions it as a key player in the medical devices market.